Immutrin is a biotechnology company developing next-generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis. This company's lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best-in-class treatment engineered to selectively and specifically remove established amyloid fibrils.